The generation and sharing of antimicrobial resistance, use and consumption (AMR/U/C) data is invaluable for underpinning national and global AMR prevention and control strategies. However, these efforts are of limited use if such data and research findings are not simultaneously transformed into policy and practice actions.
The Lancet: Global, regional, and national sepsis incidence and mortality
Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study published in The Lancet.
This paper highlights that despite decades of progress in healthcare, infectious diseases (the underlying causes of sepsis) remain a major cause of illness and death. The estimates provided in the paper are an important step in quantifying the impact of sepsis in low income countries. The Fleming Fund aims to improve surveillance capacity to generate primary data on the causes of sepsis, and especially the contribution of bacterial antimicrobial resistance. This is a critical step in improving the use of antibiotics so that their effectiveness is preserved for those who need them.
More Like This
Studies & Reports
In 2017, the researchers of the Institute for Health Metrics and Evaluation (IHME) and the University of Oxford developed a partnership to establish the human cost (burden) of AMR. This partnership gave birth to the Global Research on Antimicrobial Resistance (GRAM) project. Fast forward four years, 434 million individual records and 12,582 study-location-years' worth of data, and GRAM has become a household name for anyone in the industry.